The region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.
ADVERTISEMENT
A UK Biobank analysis of data from 200,000 people over more than ten years,
carried out by British researchers, have linked consumption of ultra-processed foods to an
increased risk of developing and dying from cancer. However, according to the authors from
Imperial College London it doesn’t provide a causal relationship.
The switch from lab-scale to industrial-scale AAV production requires deep hands-on expertise in various technological solutions, their limitations, and their suitability for GMP large-scale manufacturing. Direct application of lab-scale process leads to expensive AAV-based products and unnecessarily laborious industrial processes. The complexity and growing demands for controllable critical quality attributes (CQAs), create a challenging blend.
Biomanufacturing?Implementing high-quality process development that considers GMP manufacturing from the start is critical to reducing costs and timeline disruptions associated with raw material supply chain insecurity, adhering to regulatory compliance, and avoiding process re-design at a later stage.
Biotech innovator Biosyntia ApS, the latest addition to the ECBF, is applying proprietary biological processes to produce sustainable nutritional ingredients – a mission that has captured the imagination of seasoned biotech investors and major ingredient players.
Sweden’s Belach Bioteknik has been partnering mostly with researchers and pharma customers to design suited bioreactor systems for biomanufacturing. Most recently, the company has entered the growing cultured meat sector, in which many companies are currently scaling up their production and thus need expertise to get optimal results.
The Berlin-Brandenburg capital region is one of the leading life science regions in Europe and a lot is being done to keep it that way: with a wide variety of space offerings and support programs for founders and start-ups.
In soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germany’s top research – whispers at best, just whispers, but no outcry anywhere.
The extension, which was celebrated with an official groundbreaking ceremony, will connect the IZB campus in Martinsried to the Munich subway system.
Toulouse White Biotech (TWB) is a good example to how scaling and collaboration through production partnerships can help the industrial biotech sector to satisfy the urgent need to speed up and scale sustainable processes for industrial production.